Catalog Advanced Search

Search by Category
Search by Format
Sort By
Search by Type
Search by Category
Search in Packages
Search by Format
Search by Type
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Start
End
Search by Keyword
Sort By
  • Contains 2 Component(s) Recorded On: 03/15/2022

    Webinar hosted by the Portal Hypertension: Clinical and Experimental Special Interest Group on Tuesday, March 15, 2022.

    This webinar will address endovascular management of portal hypertensive complications using TIPS. Speakers will assess evidence for the use of TIPS in the setting of portal and mesenteric vein thromboses and how this may impact portal HTN, survival, as well as transplant outcomes. Speakers will also discuss the standard and emerging indications for TIPS as well as future directions for TIPS management in portal HTN.

    Virginia Hernandez-Gea

    Virginia Hernández-Gea, MD, PhD is a interventional hepatologist at the liver unit at hospital clinic. She is fully dedicated to the management of patients with portal hypertension and vascular liver diseases as well as conducting liver catheterization procedures including TIPS. She also runs a translational laboratory focused on the understanding of the role of the liver endothelium in liver diseases.

    Dr. Hernández-Gea is a member of the EASL Governing Board and author of more than 120 publications. She has serves as editorial boar member of Hepatology and Liver international. She is currently member of the Portal Hypertension Special Interest Group for the American Association for the Study of Liver Diseases (AASLD), Secretary of VALDIG  (Vascular Liver Disease Interest Group) and faculty of Baveno. As an active teacher and educator, she has directed 5 doctoral thesis and is assistant professor at the university of Barcelona.

    Riad Salem

    Riad Salem, MD, MBA is Professor of Radiology, Surgery and Medicine, Vice-Chair, Image-Guided Therapy and Section Chief, Interventional Radiology in the Department of Radiology at Northwestern University in Chicago. His areas of interest include the use of image-guided techniques for the treatment of liver cancer including chemoembolisation, bland embolization and radioembolisation. He is a graduate of McGill University in Montreal, where he was recipient of the Wood Gold Medal and J Francis Award in Internal Medicine. He then completed his residency in Washington DC, a fellowship in interventional radiology (University of Pennsylvania), as well as a Master’s in Business Administration (Finance).

    Dr. Salem is a member of Alpha Omega Alpha medical honor society and a Fellow of the Society of Interventional Radiology. He has delivered >800 lectures nationally and internationally, and written extensively on the subject of interventional oncology and portal hypertension (TIPS), with over 370 publications, 28000 citations, and an h index of 92. His current research focus on: 1) hepatocellular carcinoma advances in minimally invasive therapies, 2) imaging methodologies following locoregional treatment, and 3) treatment of portal vein thrombosis in cirrhotics and non-cirrhotic using novel TIPS techniques, with conversion of untransplantable patients to transplant candidacy. He serves as PI of two, international, randomized phase III trials involving sorafenib +/- Y90 in HCC (STOP-HCC) and chemotherapy +/- Y90 in CRC (EPOCH); EPOCH was the first large-scale RCT to meet its endpoints in the field of interventional oncology. He was also lead investigator in LEGACY, the pivotal trial that lead to the FDA’s first PMA device approval.

    Elizabeth Verna (Moderator)

    Elizabeth Verna, MD, MS is an Associate Professor of Medicine in the Center for Liver Disease and Transplantation and Division of Digestive and Liver Diseases at Columbia University, where she practices as transplant hepatologist. In addition, Dr. Verna has an active clinical research program in end-stage liver disease and liver transplantation and is the Director of Clinical Research for the Columbia University Transplant Clinical Research Center.

  • Contains 2 Component(s) Recorded On: 02/23/2022

    Webinar hosted by the Inclusion and Diversity Committee on Wednesday, February 23.

    The purpose of this webinar is to discuss action items for the AASLD and academic institutions. These action items will focus on efforts to improve diversity, equity and inclusion in all aspects of the hepatology continuum, including the hepatology work force as well as racial disparities in hepatology care. The webinar will include a formal 10-minute overview of the concepts of diversity, equity and inclusion and another 10-minute formal presentation on proposed future directions outlined in the white paper. There will then be a 20-minute moderated discussion between panelist discussing perceived and actual barriers to these action items. The webinar will conclude with a 10-minute question and answer portion involving all faculty.

    Be sure to check out the additional resources in the Handouts section.

    Miguel H. Malespin

    Miguel H. Malespin M.D. is a transplant hepatologist at Tampa General Hospital and associate professor for the University of South Florida College of Medicine. He earned his medical degree at Ponce Health Sciences University in Puerto Rico. Dr. Malespin continued his training in internal medicine and gastroenterology at the University of Illinois at Chicago. He then completed a fellowship in transplant hepatology at Loyola University Medical Center. His areas of clinical and research interest include non-alcoholic fatty liver disease, viral hepatitis, and health disparities. He is an active member of the AGA and AASLD serving in multiple roles and committees.

    Carla W. Brady

    Carla Brady, MD, MHS, FAASLD is an Associate Professor in the Division of Gastroenterology at Duke University Medical Center, having been a faculty member within the division since 2006. She is a transplant hepatologist and has a particular interest in liver disease and liver transplantation from a women's health perspective. Dr. Brady is the author of manuscripts on and has given talks locally, regionally, and nationally on liver disease in pregnancy, pregnancy in transplant patients, liver disease and liver transplantation in menopausal women, and disparities in liver disease care. As an active member of the American Association for the Study of Liver Diseases (AASLD), she has served on its Scientific Program Committee and Nominating Committee. She has also served as chair of the AASLD Program Evaluation Committee and as chair of the AASLD Inclusion and Diversity Committee. Locally, she has served as an elected member of the Executive Committee of the Academic Council of Duke University, a steering committee member for the Duke University Academic Council Diversity Task Force and as a co-chair of its subcommittee on Best Practices in Faculty and Administrative Diversity. 

    Lauren D. Nephew (Moderator)

    Lauren D. Nephew, MD, MA, MSCE is Assistant Professor of Medicine in the Division of Gastroenterology and Hepatology at Indiana University School of Medicine.  Her research interests include understanding barriers to liver transplantation for vulnerable populations, disparities in care of patients with hepatocellular carcinoma, and the impact of the social and structural determinants of health on the outcomes of patients with liver disease. Dr. Nephew’s clinical work focuses on both decompensated liver disease patients being evaluated for liver transplantation as well as patients with chronic liver disease.  She is the chair of the Intersociety Group on Diversity and the chair of the AASLD Inclusion and Diversity Committee.

    Dr. Nephew attended medical school at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.  She completed residency at Massachusetts General Hospital and Gastroenterology and Liver Transplantation Fellowships at the University of Pennsylvania. While at Case Western Reserve University, Dr. Nephew completed a Masters program in Clinical Bioethics.   While at the University of Pennsylvania, Dr. Nephew completed a Masters of Science in Clinical Epidemiology.  Dr. Nephew is a health equity champion, wife, and mother of two. 

    Naudia L. Jonassaint

    Naudia L. Jonassaint, MD, MHS currently is an Associate Professor of Medicine and Surgery at the University of Pittsburgh School of Medicine. She is currently serving as the Vice Chair of the Diversity, Equity and Inclusion in the Department of Medicine and the Associate Dean of Clinical Affairs in School of Medicine. Dr. Jonassaint has a specific interest in disparate outcomes in liver disease and is also uniquely interested in diversity and inclusion in academic training.

    Dr. Jonassaint is currently serving on the Finance Committee for the American Association for the Study of Liver Diseases (AASLD) as well as serving on the editorial board for Liver Transplantation. Her collaborative research focuses the optimization of care for pre-transplant liver patients including transplant selection in addition to a focus on disparities in liver transplant outcomes. As an active teacher and educator, she has mentored many undergraduate, graduate and medical students as well as junior faculty and staff at the University of Pittsburgh and beyond.  

    Sonali Paul

    Sonali Paul is a transplant hepatologist and Assistant Professor of Medicine at the University of Chicago. She is also the director of the Metabolic and Fatty Liver clinic. She has an interest in non-alcoholic fatty liver disease, obesity medicine, organ allocation, health disparities, and shared decision making between patients and providers. She received an MD from Tufts University School of Medicine. She completed her internal medicine residency at Massachusetts General Hospital and returned to Tufts for her fellowship training in gastroenterology. She also earned an MS in clinical and translational science from the Sackler School of Graduate Biomedical Sciences at Tufts University. She completed an advanced hepatology fellowship at Massachusetts General Hospital in 2016 and joined the University of Chicago faculty shortly thereafter. 

    Laurie D. DeLeve

    Laurie D. DeLeve, MD, PhD, FAASLD has been on the faculty at the University of Southern California in Los Angeles since 1990 and is Professor of Medicine and Vice Chair for Scientific Affairs in the Department of Medicine at the Keck School of Medicine. She received her MD at the Erasmus University of Rotterdam in the Netherlands and her PhD at the University of Toronto in Canada. She did her training in Internal Medicine at the University of Michigan in Ann Arbor, followed by a fellowship in Gastroenterology/Hepatology at UCLA. Dr. DeLeve is a physician-scientist and is involved in patient care, basic research, and education of medical student, residents, and Fellows.

    Dr DeLeve’s NIH-funded research has focused on the biology and pathobiology of liver sinusoidal endothelial cells (LSECs). Early work from her laboratory demonstrated that LSECs were the initial target in sinusoidal obstruction syndrome and these studies provided significant insight into the mechanisms of this syndrome. Subsequent research examined the role of LSECs in other forms of liver injury. Dr DeLeve’s lab demonstrated that LSECs maintain hepatic stellate cell quiescence, that LSEC capillarization prior to fibrosis is permissive for hepatic stellate cell activation and why that is so.  In recent years, Dr. DeLeve’s lab was the first to identify resident and bone marrow sinusoidal endothelial cell progenitor cells, so-called bone marrow sprocs. Her laboratory has examined the role of bone marrow sprocs in acute and chronic liver injury.

  • Contains 34 Component(s), Includes Credits Recorded On: 02/21/2022

    The overall goal is to improve patient care by increasing learner competence and confidence in both proper patient identification and assessment and increasing learner performance in therapeutic options and on-treatment management strategies for patients. Patient outcomes will be improved as a result of the improvements in more providers understanding these key components in the management and care of patients with liver diseases.

    DESCRIPTION
    The overall goal is to improve patient care by increasing learner competence and confidence in assessment and management of patients with alcohol-associated liver disease. The current content is geared towards increasing learner performance in therapeutic options and on-treatment management strategies for patients. Patient outcomes will be improved because of the improvements in more providers understanding these key components in the management and care of patients with alcohol-associated liver disease. 

    Improving patient care by increasing learner competence and confidence in both proper patient identification and assessment and increasing learner performance in therapeutic options and on-treatment management strategies for patients. Patient outcomes will be improved as a result of the improvements in more providers understanding these key components in the management and care of patients with alcohol-associated liver disease.

    KEY TOPIC AREAS
    Epidemiology and Disease Burden [12 minutes]
    Clinical Presentation of Alcohol-associated Liver Disease [15 minutes]
    Systemic Concomitant Manifestations [17 minutes]
    Diagnosis of Alcohol-associated Liver Disease [20 minutes]
    Diagnosis and Management of Alcohol Use Disorder [24 minutes]
    Current Medical Treatment Options [24 minutes]
    Liver Transplantation [25 minutes]
    Integrated Care Model to Treat Dual Pathology [23 minutes]
    Pathogenesis and Emerging Therapies [20 minutes]
    Prevention and Public Health Measure [16 minutes]

    Release date: February 21, 2022
    Expiration date: February 20, 2025
    Time to complete each module: 30 minutes

    CREDITS OFFERED
    Continuing Medical Education (CME): For a maximum of 5.00 AMA PRA Category 1 Credits™  
    Continuing Education (CE): For a maximum of 5.00 Contact Hour 
    You may only earn one Continuing Education Credit type - either CME or CE

    Maintenance of Certification (MOC): For a maximum of 5.00 MOC Points

    COMPONENTS Online presentations comprised of:
    -10 online interactive, narrated modules 10 to 25 minutes in length
    -Pre- and post-test questions for each module [5-10 minutes per module]
    -Evaluation for CME or CE credit offering [5-10 minutes]

    DIRECTIONS
    Click "Register" to activate the enduring material. Review all section tabs before you begin. Select module of interest. Complete all components to claim either CME or CE. MOC is available for learners who complete and earn CME.

    COPYRIGHT 
    All faculty in this activity have given their permission for publication ©2022 AASLD. 

    CONTACT INFORMATION 
    For questions on CME and MOC content or LiverLearning®, contact online_education@aasld.org 
    For questions on CE credit for this enduring material, contact Certificate@AmedcoEmail.com

    After the completion of this course, the learner will be able to:

    • Identify alcohol associated liver disease
    • Apply diagnostic tests appropriately to characterize the disease severity
    • Discuss important counseling for long term success
    • Recognize treatment/referral priorities
    • Identify first line therapies, ongoing clinical trials and follow up to improve long term outcomes

    This curriculum was developed for Primary Care Providers and any other healthcare provider interested in liver disease.

    Hepatologists
    Gastroenterologists
    Nurses
    Nurse Practitioners
    Pharmacists
    Physician Assistants
    Transplant Coordinators
    Surgeons
    Fellows/Trainees
    Primary Care Physicians
    Other healthcare providers

    CREDITS OFFERED 
    Continuing Medical Education (CME): For a maximum of 5.00 AMA PRA Category 1 Credits™ 
    Maintenance of Certification (MOC): For a maximum of 5.00 MOC Points
    Continuing Education (CE): For a maximum of 5.00 Contact Hours

    ACCREDITATION AND DESIGNATION STATEMENTS  
    Continuing Medical Education (CME)  The American Association for the Study of Liver Diseases (AASLD) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. AASLD designates this enduring activity for a maximum of 5.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Maintenance of Certification (MOC) 
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5.00 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    image

    Continuing Education (Nursing Contact Hours)  
    In support of improving patient care, this activity has been planned and implemented by Amedco LLC and the American Association for the Study of Liver Diseases.  Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Credit Designation Statement – Amedco LLC designates this enduring material activity for a maximum of 5.00 contact hours for nurses. Learners should claim only the credit commensurate with the extent of their participation in the activity.

    CLAIMING CME CREDITS 
    Physicians and other health care professionals for a maximum of 5.00 AMA PRA Category 1 Credits™ for this enduring continuing medical education material must completed by February 20, 2025

    CLAIMING CE CREDITS
    Nurses for a maximum of 5.00 contact hours for this enduring continuing education material must be completed by February 20, 2025

    CLAIMING ABIM MOC POINTS  
    Physicians seeking ABIM MOC credit must complete the enduring material by February 20, 2025. Requests for MOC after this date will not be honored. MOC Points will be reported to the ABIM by the end of each month through March 2025 for individuals who successfully complete MOC.

    HOW TO EARN AND CLAIM MOC POINTS For each module that you wish to claim MOC points for you must:

                 o    Complete the pre-tests

                 o    Watch video presentations

                 o    Complete the post-tests and pass with a score of 70% or higher (Participants have unlimited attempts to earn the passing  score.)

                 o    Claim CME credits (ABIM Rule: MOC points must be equivalent to the amount of CME credits claimed for the activity.)

    MOC completions are collected on the 15th of each month and submitted to the ABIM by the last day of the month. Points are not submitted automatically and will not display immediately on your ABIM MOC Profile.

    MOC points are available for ABIM board certified physicians only.

    DISCLOSURE OF CONFLICTS OF INTEREST

    AASLD requires all individuals who are in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial entity producing health-care related products and/or services. Disclosures are collected prior to the start of the educational activity any potential conflicts of interest that exist are resolved prior to implementation of the activity. All disclosures are made available and communicated to the leaner prior the activity beginning. The faculty, organizers and reviewers have reported the following disclosures:

    Juan P. Arab, MD
    Faculty
    Nothing to Disclose

    Suthat Liangpunsakul, MD, MPH, AGAF, FAASLD
    Faculty
    Scientific Consultant/Advisor to Industry or Commercial Enterprise, including Development of Educational Presentations: Durect Corporation, TwoXar, Surrozen

    Gene Y. Im, MD
    Faculty
    Nothing to disclose

    Michael R. Lucey, MD, FAASLD
    Faculty
    Research Grants: Abbvie; NIAAA; PharmaSolutions; Intercept Pharma; Exact Sciences
    Scientific Consultant/Advisory to Industry or Commercial Enterprise, including Development of Educational Presentations: Novartis 

    Lorenzo Leggio, MD, PhD
    Faculty
    Intellectual Property Rights (Patents, Royalties, Licensing fees): Royalties for textbook edited by Routledge

    Craig J. McClain, MD, FAASLD
    Faculty
    Research Grants: NIH, VA, GenFit, Target NASH, Diapharma, Gilead, Intercept, Novartis
    Scientific Consultant/Advisor to Industry or Commercial Enterprise, including Development of Educational Presentations: US Federal Trade Commission

    Ashwani K. Singal, MD, MS, FACG, FAASLD
    Faculty
    Scientific Consultant/Advisor to Industry or Commercial Enterprise, including Development of Educational Presentations: CLD Foundation, Medscape Gastroenterology, Up-To-Date.
    Research Grants: American College of Gastroenterology, National Institute of Alcohol Abuse and Alcoholism, National Institute of Digestive Diseases Diabetes and Kidney Diseases, GiLead

    Gerald (Scott) Winder, MD
    Faculty
    Nothing to disclose

    Gyongyi Szabo, MD, PhD, FAASLD
    Faculty
    Research Grants: NIH-NIAAA, Gilead
    Scientific Consultant/Advisor to Industry or Commercial Enterprise, including Development of Educational Presentations: AASLD, Alinylam Pharma, Intercept, Novartis, Allergan, Glympse Bio, Generon

    Lauren D. Nephew, MD, MSCE
    Faculty
    Nothing to disclose

    Amanda J. Chaney, DNP, APRN, FNP-BC
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Royalties: Springer Publishing-Author 

    Rena Fox, MD 
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Grant/Research Support: Gilead Sciences

    Sonal Kumar, MD 
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Scientific Consultant/Advisory to Industry or Commercial Enterprise, including Development of educational Presentations: Gilead Sciences, Intercept and AbbVie 
    Speaker's Bureau: Gilead Sciences and AbbVie
    Grant/Research Support: Gilead Sciences, AbbVie and Intercept

    Adam Mikolajczyk, MD 
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Nothing to disclose

    April G. Morris, FNP
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Speaker's Bureau: Gilead, AbbVie, Intercept Pharmaceuticals
    Scientific Consultant/Advisory to Industry or Commercial Enterprise, including Development of educational Presentations: AbbVie

    Paul Pockros, MD
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Nothing to disclose

    Amol Rangnekar, MD 
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Nothing to disclose

    Raj Vuppalanchi, MD, FAASLD 
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Data Safety Monitoring Board for Industry or Commercial Enterprise: Enanta, Enyio and LabCorp/Covance
    Served as PI for multicenter clinical trials: Intercept, Gilead, Zydus Discovery, Novo Nordisk and Eli Lilly

    Susan Zapatka, DNP 
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Nothing to disclose

    Dominique Clayton 
    AASLD Staff
    Nothing to disclose

    Sheryl Morgan
    Amedco LLC Staff
    Nothing to disclose

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    DISCLAIMER
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

    Acknowledgement of Commercial Support: No commercial support was received for this enduring material activity.

  • Product not yet rated Contains 2 Component(s) Recorded On: 02/08/2022

    Webinar hosted by the Membership and Mentorship Committee on Tuesday, February 8, 2022.

    This webinar, sponsored by the AASLD Membership and Mentorship Committee, will consist of three lectures from three mid-career faculty who have directly benefited from mentoring to achieve career success. As part of this educational webinar, the attendee will learn how the proper mentor can help a mentee attain their career goals while maintaining work-life balance. The attendee will also learn the art of menteering, to gain the most out of their relationship with their mentor. Finally, this webinar will introduce attendees to the new AASLD pilot program to bring potential mentees and mentors together in a virtual format.

    Vinay Sundaram

    Vinay Sundaram, MD, MSc is currently an Associate Professor of medicine and Director of Hepatology Outcomes Research at Cedars-Sinai Medical Center. He completed medical school at NYU School of Medicine, followed by a residency at the University of Virginia, gastroenterology fellowship at the University of Pittsburgh, and a transplant hepatology fellowship at Beth Israel Deaconess Medical Center.

    Dr. Sundaram has published more than 100 manuscripts including first authored papers in Gastroenterology, HEPATOLOGY, Journal of Hepatology and Liver Transplantation. He currently serves on the AASLD Acute on Chronic Liver Failure Special Interest Group’s steering committee and is the current chair of the AASLD Membership and Mentorship Committee. He is also on the editorial boards of HEPATOLOGY, American Journal of Gastroenterology and Hepatology Communications and previously served as on the UNOS membership and professional standards committee.

    Elliot B. Tapper

    Elliot Tapper, MD is Assistant Professor of Medicine at the University of Michigan Health System. Dr. Tapper’s research aims to improve the outcomes, quality of life and freedom from adverse events for patients with cirrhosis. His efforts focus on delineating quality indicators and developing interventions for the management and prevention of cirrhotic complications. His work on patient-centered, cost-effective diagnostic strategies for elevated liver enzymes have been published in journals including the American Journal of Gastroenterology, Journal of Hepatology, JAMA Internal Medicine, and the New England Journal of Medicine.

    Jennifer A. Flemming

    Jennifer A Flemming, MD, FRCPC, MAS is an ICES Scientist and Associate Professor of Medicine and Public Health Sciences for the Division of Gastroenterology at Queen’s University in Ontario Canada. She has advanced clinical training in hepatology and liver transplantation in addition to a master’s degree in clinical research from the University of California San Francisco. She is a clinician scientist who runs a research program which leverages the administrative healthcare databases in Ontario held at ICES to perform population based epidemiologic research in patients with chronic liver diseases, cirrhosis, and primary liver cancer with a special focus on underrepresented populations such as women and immigrants/refugees.

    Dr. Flemming is currently a member of the AASLD Women’s Initiatives Committee, Chair of the Guidelines Committee for the Canadian Association for the Study of Liver Disease (CASL) and a member of the CASL Equity and Diversity Committee. Her research program has been supported by the AASLD Foundation, the American Gastroenterological Association (AGA) and the Canadian Donation and Transplantation Research Program. She was the recipient of the 2021 CASL Research Excellence Award and has authored over forty peer-reviewed publications in leading journals such as Gastroenterology, Hepatology, and Lancet Gastroenterology and Hepatology. She is the incoming site director for ICES-Queen’s, a not-for-profit research institute encompassing a community of research, data and clinical experts, and a secure and accessible array of Ontario's health-related data. As an active teacher and educator, she has mentored over twenty-five trainees from undergraduate, to medical, Masters’ and PhD students in Public Health Sciences, clinical residents/fellows, and faculty at the Assistant Professor rank from Queen’s University as well as other institutions in the U.S. and Canada.

    Enis Kostallari (Moderator)

    Enis Kostallari, PhD is an Associate Consultant in the Division of Gastroenterology and Hepatology, an Assistant Professor of Medicine and an Assistant Professor of Biochemistry and Molecular Biology at Mayo Clinic. Dr. Kostallari’s research focuses on the pathobiology of non-parenchymal cells in liver fibrosis. More specifically, she investigates the intracellular mechanisms in the hepatic stellate cells which lead to the release of fibrogenic extracellular vesicles and ultimately liver fibrosis. In the past two years, Dr. Kostallari’s studies have been published in major journals such as Journal of Hepatology and Hepatology where she was the lead principal investigator and co-principal investigator, respectively.

    In addition to her science, Dr. Kostallari serves as a peer-reviewer for major journals, such as HepatologyJournal of HepatologyGastroenterologyJournal of Clinical InvestigationEMBO, and others, and is currently a guest editor for Frontiers in Molecular Biosciences. She has been an external reviewer for grant proposals in Belgium and France and is currently a writer for the Hepatology Highlights section in the Hepatology journal. She is a steering committee member of the AASLD Liver Fibrosis special interest group and a committee member of the Membership and Mentorship Committee. At Mayo Clinic, Dr. Kostallari is the chair of the Extracellular Vesicle interest group and a course instructor. As an active mentor, during her career she has supervised several trainees, from high school to undergraduate, medical, Masters’, PhD students, postdoctoral fellows and visiting scientists from institutions in the U.S. and overseas.

  • Contains 28 Component(s), Includes Credits Recorded On: 01/25/2022

    Addiction Medicine for Liver Care Providers Course

    DESCRIPTION

    There is growing interest among hepatology providers in incorporating addiction medicine skills in the evaluation of patients with addiction-related liver diseases, particularly alcohol-associated liver disease. Recent studies have shown an association between receipt of addiction treatment and improvements in liver-related outcomes in patients with alcohol-associated liver disease. Furthermore, a survey by the AASLD Alcohol-Associated Liver Disease Special Interest Group examining hepatology provider knowledge and attitudes toward the identification and treatment of alcohol use disorder revealed that 90% of respondents felt the need for additional training. Substance use disorders beyond alcohol use disorder can impact candidacy for liver transplantation as well as other liver-related outcomes. Given the rising prevalence of alcohol-associated liver disease and high burden of substance use disorders in the United States, arming liver care providers with skills to address addiction among their patients can have a significant clinical and public health impact. The purpose of this course is to provide a focused overview of key addiction medicine topics and how they relate to the care of patients with chronic liver disease.  

    KEY TOPIC AREAS
    -Biological Basis and Approach to Substance Use Disorders [30 minutes]
    -Screening, Diagnosis and Monitoring of Substance Use Disorders [30 minutes]
    -Behavioral and Pharmacological Therapies for Substance Use Disorders [30 minutes]
    -Management of Alcohol Use Disorder [45 minutes]
    -Management of Opioid Use Disorder [40 minutes]
    -Management of Tobacco Use Disorders [30 minutes]
    -Management of Cannabis, Stimulant and Sedative-Hypnotic Use Disorders [45 minutes]
    -Integrating Addiction and Hepatology Care [40 minutes]

    Release date: January 25, 2022
    Expiration date: January 24, 2025
    Time to complete each module: 30-45 minutes

    CREDITS OFFERED
    Continuing Medical Education (CME): For a maximum of 6.00 AMA PRA Category 1 Credits™  
    Continuing Education (CE): For a maximum of 6.00 Contact Hour 
    You may only earn one Continuing Education Credit type - either CME or CE

    Maintenance of Certification (MOC): For a maximum of 6.00 MOC Points

    COMPONENTS
    Online presentations comprised of:
    -Eight online narrated modules 30 to 45 minutes in length
    -Pre- and Post-test [5-10 minutes per module]
    -Evaluation for CME or CE credit offering [5-10 minutes]

    DIRECTIONS
    Click "Register" to activate the enduring material. Review all section tabs before you begin. Select module of interest. Complete all components to claim either CME or CE. MOC is available for learners who complete and earn CME.

    COPYRIGHT 
    All faculty in this activity have given their permission for publication ©2022 AASLD. 

    CONTACT INFORMATION 
    For questions on CME and MOC content or LiverLearning®, contact online_education@aasld.org 
    For questions on CE credit for this enduring material, contact Certificate@AmedcoEmail.com

    After the completion of this course, the learner will be able to:

    • Describe the biological basis, epidemiology and general approach to addiction treatment
    • Identify and facilitate treat for common substance use disorders, including alcohol use disorder, opioid use disorder, tobacco use disorder and others
    • Recognize ways of integrating addiction treatment into hepatology care settings

    This course was developed for Primary Care Providers and any other healthcare provider interested in liver disease.

    Hepatologists
    Gastroenterologists
    Nurses
    Nurse Practitioners
    Physician Assistants/Physician Associates
    Transplant Coordinators
    Surgeons
    Fellows/Trainees
    Primary Care Physicians
    Other healthcare providers

    CREDITS OFFERED 
    Continuing Medical Education (CME): For a maximum of 6.00 AMA PRA Category 1 Credits™ 
    Maintenance of Certification (MOC): For a maximum of 6.00 MOC Points
    Continuing Education (CE): For a maximum of 6.00 Contact Hours

    ACCREDITATION AND DESIGNATION STATEMENTS  
    Continuing Medical Education (CME)  The American Association for the Study of Liver Diseases (AASLD) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. AASLD designates this enduring activity for a maximum of 6.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Maintenance of Certification (MOC) 
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.00 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    image

    Continuing Education (Nursing Contact Hours)  
    In support of improving patient care, this activity has been planned and implemented by Amedco LLC and the American Association for the Study of Liver Diseases.  Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Credit Designation Statement – Amedco LLC designates this enduring material activity for a maximum of 6.00 contact hours for nurses. Learners should claim only the credit commensurate with the extent of their participation in the activity.

    CLAIMING CME CREDITS 
    Physicians and other health care professionals for a maximum of 6.00 AMA PRA Category 1 Credits™ for this enduring continuing medical education material must completed by January 24, 2025

    CLAIMING CE CREDITS
    Nurses for a maximum of 6.00 contact hours for this enduring continuing education material must be completed by January 24, 2025

    CLAIMING ABIM MOC POINTS  
    Physicians seeking ABIM MOC credit must complete the enduring material by January 24, 2025. Requests for MOC after this date will not be honored. MOC Points will be reported to the ABIM by the end of each month through January 2025 for individuals who successfully complete MOC.

    HOW TO EARN AND CLAIM MOC POINTS For each module that you wish to claim MOC points for you must:

                 o    Complete the pre-tests

                 o    Watch video presentations

                 o    Complete the post-tests and pass with a score of 70% or higher (Participants have unlimited attempts to earn the passing  score.)

                 o    Claim CME credits (ABIM Rule: MOC points must be equivalent to the amount of CME credits claimed for the activity.)

    MOC completions are collected on the 15th of each month and submitted to the ABIM by the last day of the month. Points are not submitted automatically and will not display immediately on your ABIM MOC Profile.

    MOC points are available for ABIM board certified physicians only.

    DISCLOSURE OF CONFLICTS OF INTEREST

    AASLD requires all individuals who are in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial entity producing health-care related products and/or services. Disclosures are collected prior to the start of the educational activity any potential conflicts of interest that exist are resolved prior to implementation of the activity. All disclosures are made available and communicated to the leaner prior the activity beginning. The faculty, organizers and reviewers have reported the following disclosures:

    Sarah Wakeman, MD
    Faculty
    Research Support: Optum Labs
    Advisory Committees or Review Panels: Celero Systems
    Author: UpToDate

    Jeffrey Samet, MD, MA, MPH
    Faculty
    Nothing to disclose

    Dana Cavallo, PhD
    Faculty
    Nothing to disclose

    Melissa Weimer, DO, MCR, FASAM
    Faculty
    Consulting: Path, CCM Inc.
    Advisory Committees or Review Panels: American Society of Addiction Medicine
    Grant/Research Support: NIH NIDA

    Tiffany Lu, MD, MS
    Faculty
    Grant/Research Support: HRSA, SAMHSA, NIH NIDA
    Author: UpToDate

    Stephen Baldassarri, MD
    Faculty
    Nothing to disclose

    Linda Peng, MD
    Faculty
    Nothing to disclose

    Gerald (Scott) Winder, MD
    Faculty
    Nothing to disclose

    Lamia Haque, MD, MPH
    Online Learning Committee/Organizer/Reviewer
    Nothing to disclose 

    Oren K. Fix, MD, MSc, FAASLD  
    Online Learning Committee/Organizer/Reviewer
    Nothing to disclose

    Andrew Paul Keaveny, MD, FRCPI, FAASLD 
    Online Learning Committee/Organizer/Reviewer
    Advisory Committees or Review Panels: UpToDate; American Board of Internal Medicine
    Grant/Research Support: Mallinckrodt Medical Inc; HepQuant LLC. (Title of study: The SHUNT-V Study for Varices); Regeneron Pharmaceuticals; Gabriel House of Care

    Omar Mousa, MD 
    Online Learning Committee/Organizer/Reviewer
    Nothing to disclose 

    Nicole E. Rich, MD 
    Online Learning Committee/Organizer/Reviewer
    Scientific Consultant/Advisory to Industry or Commercial Enterprise, including Development of educational Presentations: AstraZeneca

    Robert Mitchell-Thain
    Online Learning Committee/Reviewer
    Nothing to disclose

    Arnab Mitra, MD 
    Online Learning Committee/Reviewer
    Nothing to disclose

    Rohit S. Satoskar, MD, FAASLD 
    Online Learning Committee/Reviewer
    Stock/Stock Options with Relevant Pharmaceutical or Biotechnology Companies: Pfizer

    Megan Glynn
    Online Learning Committee
    Nothing to disclose

    Sanjiv Harpavat, MD, PhD 
    Online Learning Committee
    Data Safety Monitoring Board for Industry or Commercial Enterprise: Syneos

    Paul Martin, MD, FAASLD
    Online Learning Committee
    Grant/Research Support: AbbVie, Thera and Mallinckrodt

    Dominique Clayton 
    AASLD Staff
    Nothing to disclose

    Sheryl Morgan 
    Amedco LLC Staff
    Nothing to disclose

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    DISCLAIMER
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

    Acknowledgement of Commercial Support: No commercial support was received for this enduring material activity.

  • Contains 2 Component(s) Recorded On: 01/11/2022

    Webinar hosted by the Hepatitis B Special Interest Group on Tuesday, January 11, 2022.

    The goal of this webinar is to review mechanisms of HBV DNA integration in the context of potential clinical relevance including HCC, clinical monitoring, treatment and emerging therapeutics towards a functional cure. Some questions to be explored re: HBV DNA integration in this webinar: What is it? How/when does it happen? What is its potential impact in liver disease pathogenesis and clinical outcome (e.g. HCC)? What are potential impact of HBV DNA integration on timing of treatment initiation, clinical monitoring and novel therapeutic development?

    Stefan F. Wieland

    Stefan Wieland, PhD is a group leader at the Department of Biomedicine, University Hospital Basel, Switzerland. He completed his doctoral training at the University of Zurich, Switzerland and his post-doctoral training at the University Hospital Freiburg, Germany and the Scripps Research Institute, La Jolla, CA where he continued for over 15 years as Staff scientist and Assistant Professor. The main focus of his research was the biology and pathogenesis of hepatitis B virus (and hepatitis C virus) infection.

    Professor Wieland studied host pathogen interactions of hepatitis B virus (HBV) infection for over 20 years. These studies involved in vitro and small animal model systems and experimental HBV infection in chimpanzees. These studies established HBV as a stealth virus whereby it avoids detection by the host, nevertheless being sensitive to antiviral host responses. Recently, Stefan Wieland has expanded these studies to the virus host interactions in the liver of chronically HBV infected (CHB) patients in different disease phases.

    Irene O.L. Ng

    Irene OL Ng, MD, FAASLD is a Chair Professor in Pathology, Loke Yew Professor in Pathology and Director of the State Key Laboratory of Liver Research for The University of Hong Kong. She is a clinical  Anatomic Pathologist with a special interest in liver pathology. Her research focuses on the integrated functional genomics of liver cancer using genome-scale technologies coupled with clinical translational studies. She has an active program in the basic/translational research of liver cancer and HBV, using state-of-the art molecular approaches including genomics, transcriptomics, and single cell analysis, to address cancer pathogenesis, heterogeneity and tumor microenvironment. She is among the top 1% of most cited scientists of ISI Essential Science Indicators.

    Professor Ng is the Director of State Key Laboratory of Liver Research of The University of Hong Kong, directing many successful scientific programs in liver research. She has served as Associate Editor or Editorial/advisory board member for major journals such as HEPATOLOGY, Nature Reviews Gastroenterology and Hepatology, and Gastroenterology. Ng is currently the Governing Board and Executive Council Member for the Asia-Pacific Primary Liver Cancer Expert Association (APPLE). She is the lead Principal Investigator for theme-based and group programs funded by the Research Grants Council and the Hong Kong SAR Government. She is also Board of Directors for non-profit organization locally. She has organized international, regional and local conferences in cancer, liver and stem cell research. As an active teacher and educator, she has taught in many undergraduate and postgraduate programs at HKU. She also mentored many clinical residents/fellows, postdoctoral research fellows, and faculties at Assistant/Associate Professor at The University of Hong Kong.

    Patrick Kennedy

    Patrick Kennedy, PhD is a Professor of Translational Hepatology & Consultant Hepatologist at Barts and The London School of Medicine & Dentistry, QMUL. He trained at University College Dublin before completing post-graduate training in Gastroenterology & Hepatology in London. In 2009 he was awarded a prestigious HEFCE Clinical Senior Lectureship and set up his own research group at Barts and The London School of Medicine.  

    Professor Kennedy’s primary research focus is on HBV with a special interest in liver disease in young people. He leads the HBV service at Bart’s Health with more than 6,000 chronic HBV infected patients under follow-up. He has produced novel work redefining disease phase in HBV, the foundation for the re-evaluation of treatment candidacy. He has authored or co-authored >70 peer reviewed publications, h-index 45, and he has edited a textbook of Gastroenterology and Hepatology. His research themes of viral immunology and age-related changes in CHB are the focus of his current work towards developing individualized treatment strategies and changing the current management paradigm in chronic infection.

    Kyong-Mi Chang (Moderator)

    Kyong-Mi Chang, MD is Professor of Medicine in GI/Hepatology, University of Pennsylvania Perelman School of Medicine, with administrative leadership role as the Chief of Staff and Associate Dean for Research at the Corporal Michael J. Crescenz Veterans Affairs Medical Center in Philadelphia PA.

    Dr. Chang is a translational investigator with expertise in immune pathogenesis of human viral hepatitis B and C. Dr. Chang received M.D. and Internal Medicine residency training from the Medical College of Pennsylvania, GI fellowship training at the University of California San Diego and postdoctoral research training in viral immune pathogenesis at the Scripps Research Institute. Since the mid 90’s, Dr. Chang has examined distinct patient cohorts using state-of-the-art immunological methods and novel tools to identify immune and viral mechanisms of liver disease pathogenesis in patients with acute and chronic hepatitis B or C. Chang lab was the first to apply high dimensional imaging mass cytometry visualization of HBV-infected liver tissues, identifying close correlations between innate and adaptive immune parameters with hepatocellular injury and fibrosis. Dr. Chang has also been examining genetic underpinnings of metabolic liver disease in the VA’s Million Veteran Program (MVP). Finally, Dr. Chang has been a member of the AASLD for over 2 decades, serving in various committees and meetings--currently as Chair of HBV SIG Basic Science Subcommittee. 

    Haitao Guo (Moderator)

    Haitao Guo, PhD is a Professor in the Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, and the Co-Leader of Cancer Virology Program of Hillman Cancer Center, University of Pittsburgh Medical Center. His research is focused on the viral pathogenesis of hepatitis B virus (HBV) and antiviral discovery. The Guo laboratory aims at understanding the molecular mechanisms of HBV DNA replication and morphogenesis, with special focus on the biosynthesis and regulation of HBV covalently closed circular (ccc) DNA, which is the persistent form of HBV infection, and is the culprit for the failure of current antiviral therapies. His lab has also established the HBV cccDNA reporter cell line systems for high-throughput screening of cccDNA inhibitors. In addition, Dr. Guo studies the innate immunity and oncogenic signaling pathways that regulate HBV replication, as well as identification and characterization of host restriction factors that inhibit HBV infection and propagation in human hepatocytes. His lab is also investigating the molecular mechanisms of HBV-induced liver cancer and finding therapeutic targets.

    Dr. Guo has been serving as editor and/or editorial board member for major journals such as Hepatology, Journal of Virology, Journal of Medical Virology, Antiviral Research, etc., and he has served as the standing member of NIH Virology B Study Section. He is currently the Co-Chair of the Hepatitis B Special Interest Group for the American Association for the Study of Liver Diseases (AASLD), Co-Chair of Virology Working Group of the International Coalition to Eliminate Hepatitis B (ICE-HBV), and member of the Scientific Advisory Council of International HBV Meeting. He has served as the co-organizer of the 2015 International HBV Meeting. Dr. Guo has published more than 80 papers with an H-index of 38. He holds 3 patents and two of them have been licensed to pharmaceutical companies. Dr. Guo has trained more than 30 graduate students and postdoctoral fellows. He has served as mentor for several NIH training grants. He has also served as mentor for a NIDDK K01 recipient. Dr. Guo has been awarded the Bruce Witte Fellow of Hepatitis B Foundation, 2017 IUSM Showalter Scholar, 2017 IUPUI Research Frontiers Trailblazer Award, 2019 IU Trustee’s Teaching Award, and 2020 UPMC Hillman Senior Faculty Fellow for Innovative Cancer Research.

  • Product not yet rated Contains 5 Component(s) Recorded On: 11/11/2021

    Postgraduate Course presented at The Liver Meeting® 2021.

    Nonalcoholic fatty liver disease (NAFLD) and alcohol-associated liver disease are two principal causes of advanced liver disease in the U.S., and both contribute heavily to rising incidence of hepatocellular carcinoma. Faculty will identify drivers of disease progression in both diseases, provide guidance on optimal management strategies, and discuss emerging therapeutic options most likely to be in the future treatment armamentarium.

  • Product not yet rated Contains 2 Component(s) Recorded On: 11/11/2021

    Cholestatic and Autoimmune Liver Diseases SIG presented at The Liver Meeting® 2021.

    What is the latest evidence to guide hepatologists in the management of patients with challenging overlap syndromes, such as PBC-AIH and PSC-AIH? At this stimulating program, faculty will address current controversies related to the pathogenesis, diagnosis, and management of overlap syndromes, including how to distinguish different phenotypes and select appropriate therapeutics for these patients.

  • Product not yet rated Contains 2 Component(s) Recorded On: 11/11/2021

    Hepatology Associates SIG presented at The Liver Meeting® 2021.

    Discuss new advances in the management of liver masses at this symposium. The first talks cover the evaluation and diagnosis of liver lesions, and advances in locoregional therapy for HCC. Faculty will then review curative options for HCC, including surgical resection, liver transplantation, ablative techniques, and first- and second-line systemic chemotherapy, along with new clinical trial outcomes.

  • Product not yet rated Contains 2 Component(s) Recorded On: 11/11/2021

    Alcohol-associated Liver Disease SIG presented at The Liver Meeting® 2021.

    The healthcare burden of alcohol-associated liver disease (ALD) is rising, especially in younger adults and women, with worrying ethnic and racial disparities in ALD burden. Epidemic metabolic risk factors and obesity seem to drive higher prevalence of both ALD and NAFLD. This symposium will address ALD in special at-risk populations and how hepatologists can effectively diagnose and manage these patients.